Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences reports developments across a commercial portfolio of non-opioid pain management and regenerative health products. Its recurring updates center on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain, ZILRETTA® extended-release intra-articular corticosteroid injection for osteoarthritis, and the iovera° cold-therapy device for targeted nerve pain control.
Company news also covers earnings and product revenue trends, real-world evidence on opioid use and healthcare costs, pipeline development involving ZILRETTA, iovera° and PCRX-201, share repurchases, equity inducement awards, and stockholder governance matters tied to board composition and proxy materials.
Pacira BioSciences (PCRX) announced positive topline results from its Phase 3 study of EXPAREL for postsurgical pain management in bunionectomy patients. The study demonstrated a statistically significant reduction in pain scores and opioid consumption compared to bupivacaine HCl, meeting both primary and secondary endpoints (p<0.00001). The company plans to submit a supplemental New Drug Application early in 2023 to expand EXPAREL's label for new indications. The results position EXPAREL as a groundbreaking option for regional analgesia, aiming to enhance patient outcomes while minimizing opioid use.
Pacira BioSciences announced a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization for an expanded indication of EXPAREL in children aged 6 years and older. This allows for its use as a field block for somatic post-operative pain management from small- to medium-sized surgical wounds. The approval is based on the Phase 3 PLAY study, involving 98 pediatric patients, which showed safety and pharmacokinetic profiles similar to those in adults. A European Commission decision is expected by November 2022.
Pacira BioSciences, Inc. (Nasdaq: PCRX) reported preliminary unaudited net product sales of $59.1 million for August 2022, driven by EXPAREL sales totaling $46.7 million, up from $41.4 million in August 2021. The average daily sales for EXPAREL reached 108% of the previous year. The company has also surpassed 11 million patients treated with EXPAREL. Despite positive sales trends, Pacira refrained from providing 2022 revenue guidance due to lingering uncertainties from COVID-19 and its impact on elective surgeries.
Pacira BioSciences (Nasdaq: PCRX) announced positive topline results from a Phase 3 study of EXPAREL for postsurgical pain management after knee arthroplasty. The study demonstrated a statistically significant reduction in cumulative pain scores and opioid consumption through 96 hours compared to bupivacaine HCl (p<0.01). Following these results, Pacira plans to submit a supplemental New Drug Application to expand the EXPAREL label to include a femoral nerve block indication. The drug was well tolerated, reinforcing its position in opioid-sparing pain management.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary net product sales of $50.2 million for July 2022, driven by its flagship product EXPAREL, which achieved average daily sales of 105% compared to July 2021. EXPAREL generated $40.9 million in sales, while ZILRETTA and iovera° contributed $8.2 million and $1.1 million respectively. Despite challenges from COVID-19 affecting elective procedures, the company reported ongoing growth and plans to enhance customer training and partnerships to support product adoption.
Pacira BioSciences, Inc. (Nasdaq: PCRX) and the NFL Alumni Association have announced a partnership aimed at raising awareness for non-opioid pain management strategies.
The collaboration will educate retired players and youth sports organizations on effective alternatives to opioids for managing pain, particularly postsurgical pain and knee osteoarthritis. The program will unfold through events and educational content shared via NFLA channels through May 2025, focusing on player safety and combatting the opioid crisis.
This partnership highlights Pacira's commitment to redefining opioid use in pain management.
Pacira BioSciences (PCRX) reported a strong second quarter of 2022 with total revenues of $169.4 million, a 25% increase year-over-year, attributed to successful integration of Flexion. EXPAREL net sales were $137 million, contributing significantly to net income of $19.9 million or $0.44 per share. Adjusted EBITDA stood at $44.9 million. The company completed patient enrollment in two Phase 3 studies for EXPAREL, which may expand its indications. However, ongoing challenges related to COVID-19 could impact future revenue guidance.
TAMPA, Fla., Aug. 02, 2022 – Pacira BioSciences (NASDAQ: PCRX) will participate in the analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Aug. 10, 2022, at 11:30 AM ET. Investors can access the live audio on the company’s website, with a replay available for two weeks post-event. Pacira is focused on non-opioid treatments, marketing products like EXPAREL®, ZILRETTA®, and ioveraº®. The company's mission aims to redefine opioid use, addressing chronic pain and related conditions.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will report its Q2 financial results on August 3, 2022, before U.S. market opens. Following the report, a conference call is scheduled at 8:30 a.m. ET. The call can be accessed by dialing 1-800-715-9871 (US) or 1-646-307-1963 (international), using passcode 9287305. Interested investors can join via webcast on Pacira's investor page. The company focuses on non-opioid treatments, including EXPAREL®, ZILRETTA®, and ioveraº®, aimed at reducing opioid reliance in pain management.
Pacira BioSciences reported preliminary revenues of $169.4 million for Q2 2022, up from $135.6 million in Q2 2021. Sales were driven by EXPAREL and ZILRETTA, with average daily sales of EXPAREL at 105% of the prior year for Q2. The company is focused on expanding its portfolio of non-opioid pain management solutions. Despite pandemic disruptions, they are optimistic about growth, especially in outpatient settings. The company remains cautious about future guidance due to ongoing challenges, including labor shortages and potential COVID-19 impacts.